- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1613-7671
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Medical practice and placebo response: an inseparable bond? ; volume:132 ; number:9-10 ; day:24 ; month:3 ; year:2020 ; pages:228-231 ; date:5.2020
Wiener klinische Wochenschrift ; 132, Heft 9-10 (24.3.2020), 228-231, 5.2020
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00508-020-01626-9
- URN
-
urn:nbn:de:101:1-2020080100101439984081
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jilch, Sandra
- Sel, Ruken
- Shariat, Shahrokh F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
MRI as a screening tool for prostate cancer: current evidence and future challenges
Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images
Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
MRI as a screening tool for prostate cancer: current evidence and future challenges
Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images
Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization
Prostatakrebs : Vorbeugung, Diagnose; Therapie
Nonmuscle invasive urothelial cancer— Bacillus Calmette–Guérin instillation or checkpoint inhibitor immunotherapy?
Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette–Guérin immunotherapy for T1G3/HG bladder cancer
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients : Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer
Focal therapy in intermediate- and high-risk prostate cancer
Neoadjuvant therapy in urothelial cancer : New therapies on the horizon
Evidence and emerging trends in local therapy for metastatic hormone-sensitive prostate cancer: a narrative review
ASO Author Reflections: Is Vascular Cell Adhesion Molecule-1 (VCAM-1) a Promising Biomarker in Urothelial Carcinoma of the Bladder?
ASO Author Reflections: Is There Any Difference Among Various Gleason Scores Classified as Grade Group 4 Prostate Cancer?
MRI as a screening tool for prostate cancer: current evidence and future challenges
Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images